Trials / Available
AvailableNCT05594758
Named Patient Program for Olverembatinib (HQP1351)
Named Patient Program for Providing Access to Olverembatinib (HQP1351) to Countries Where the Drug is Not Available
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Ascentage Pharma Group Inc. · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- —
Summary
This program will allow eligible patients access to Ascentage Pharma's novel drug candidate Olverembatinib (approved in China) on a named patient basis in over 100 countries ( with the exception of the USA and China) and regions where the drug is not available.
Detailed description
Olverembatinib is a novel third generation BCR-ABL inhibitor that can effectively target a spectrum of BCR-ABL mutants, including the T315I mutation. Olverembatinib is approved in China for the treatment of adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic phase chronic myeloid leukemia (CP-CML) or accelerated-phase CML (AP-CML) harboring the T315I mutation as confirmed by a validated diagnostic test1.
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olverembatinib | Oral Olverembatinib |
Timeline
- First posted
- 2022-10-26
- Last updated
- 2024-02-07
Source: ClinicalTrials.gov record NCT05594758. Inclusion in this directory is not an endorsement.